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ZebraﬁshSpinal muscular atrophy (SMA), the leading genetic cause of infant mortality, is characterized by the degenera-
tion of spinal motor neurons and muscle atrophy. Although the genetic cause of SMA has been mapped to the
Survival Motor Neuron1 (SMN1) gene, mechanisms underlying selective motor neuron degeneration in SMA re-
main largely unknown. Herewe review the latest developments and our current understanding of themolecular
mechanisms underlying SMA pathogenesis, focusing on the animal model systems that have been developed, as
well as new diagnostic and treatment strategies that have been identiﬁed using thesemodel systems. This article
is part of a special issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive genetic
disorder characterized by the loss of spinal motor neurons, which
leads to muscle atrophy, paralysis, and ultimately death [12,54,68]. As
the primary genetic cause of infant mortality and the secondmost com-
mon autosomal recessive genetic disorder, SMA affects one in every six
thousand live births with a carrier frequency of one in forty people [72,
74,84]. More than 98% of patients with SMAhave a homozygous disrup-
tion of the Survival Motor Neuron1 (SMN1) gene on chromosome 5q13
by deletion, rearrangement, or mutation [35,49]. In addition to the
telomeric SMN1, humans also contain a centromeric SMN2 produced
by intrachromosomal duplication. SMN2 differs from SMN1 by only
ﬁve nucleotides [13,49]. One silent single nucleotide change within
exon 7 of SMN2 disrupts its splicing [16,17,44]. Thus, SMN2 produces
only a small amount of full-length functional protein and mostly an un-
stable truncated isoform of SMN lacking exon 7 (SMNΔ7). Therefore,
mutations of SMN1 lead to reduced but not depleted levels of full-
length SMN protein in SMA, which are sufﬁcient to sustain the survival
of most cell types with the exception of spinal motor neurons.
The expression level of SMN protein is inversely correlated with
SMA disease severity. The pathological symptoms are highly variable.scular Diseases: Pathology andPatients can be classiﬁed into four categories (Table 1) according to
the age of onset and maximum motor function achieved [71]. SMA
type I, or Werdning–Hoffman disease, is the most common and severe
type. Onset is usually before 6 months of age, and death occurs within
the ﬁrst 2 years of life. These infants have profound ﬂaccid symmetrical
weakness and hypotonia, and are unable to sit without support. Bulbar
denervation results in tongue weakness and fasciculation with poor
suckling and swallowing. SMA type II is of intermediate severity and
characterized by onset of disease between 7 and 18 months of age. Pa-
tients are capable of sitting independently but do not achieve the ability
to walk. Patients with SMA type III (Kugelberg–Welander disease) have
onset of symptoms after 18 months and are able to achieve indepen-
dent walking. Adult onset, or SMA type IV, starts around the second or
third decade of life and is characterized by mild weakness without re-
spiratory or nutritional problems [71]. Although themajority of patients
(95%) have homozygous deletion of SMN1 exon 7 or both exon 7 and 8,
about 3–4% of patients are compound heterozygotes for the deletion of
SMN1 on one allele and a point mutation on the other. De novo muta-
tions occur at a rate of 2% because of regional instability on chromosome
5 [56]. An updated list of SMN1 gene mutations is available on Leiden
Open Variation Database (http://www.dmd.nl/nmdb2/home.php?
select_db=SMN). Mutations include nonsense, frame-shift, missense,
deletions, inversions and splicing site changes. The Y272C and 813ins/
dup11 mutations are reported to be the most common [96].
Themain pathological feature of SMA is neuronal loss in the anterior
horn of the spinal cord with chromatolysis, neurophagia and gliosis [3,
46]. Neuromuscular junction ultrastructural abnormalities were also
noted in humans with SMA [43]. Recently, neuromuscular junction
Table 1
Classiﬁcation of spinal muscular atrophy.
Age of onset Maximum motor function achieved Age of death
Type I (severe, Werdnig–Hoffmann disease) Before 6 months Unable to sit Less than 2 years
Type II (Intermediate) 7–18 months Sit, never walk More than 2 years
Type III (mild, Kugelberg–Welander disease) After 18 months Stand and walk independently Adult
Type IV (very mild) Second or third decade Walking during adulthood Adult
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nerve stimulation. Pathological detrimental response was observed in
about half the patients with SMA type II or III, but not in control patients
or other motor neuron disease patients, suggesting speciﬁc neuromus-
cular junction dysfunction in SMA [94]. In addition, myotubes were
found to be smaller in skeletal muscle tissue from severely affected
SMA fetuses, indicating a delay in muscle growth and maturation [59].
Patients with severe SMA also develop congenital heart defect and ar-
rhythmias, vascular abnormalities such as digital necrosis and mild hy-
perglycemia, suggesting pancreatic dysfunction. The ﬁrst diagnostic test
for a patient suspected to have spinalmuscular atrophy should be SMN1
gene deletion test. If this initial test is negative, further testing, including
muscle creatine kinase level and nerve conduction studywith repetitive
nerve stimulation and electromyography, should be done. If electro-
physiological studies suggest a motor neuron disease then sequences
of both SMN1 alleles should be determined.
SMN has been implicated in several functional processes, including
pre-mRNA splicing, mRNA transport, and axon growth [1,63,64,76,80].
Although SMN is ubiquitously expressed in all tissues, spinalmotor neu-
rons are particularly vulnerable to diminished levels [68]. The underly-
ing mechanisms of spinal motor neuron susceptibility remain largely
unknown. There are, however, a number of prevailing and not mutually
exclusive hypotheses based on the data yielded from disease models
that may begin to explain. That the wild-type SMN protein has an
established function in small nuclear ribonucleoprotein (snRNP) assem-
bly suggests a role for pre-mRNA splicing in SMA disease progression
[76]. Alternatively, because motor neurons have highly specialized,
far-extending axons, it has been postulated that the localization of
mRNAs to these distal processes is affected in SMA,whichmay be a driv-
er of the selectivity for motor neuron degeneration [80]. At present, no
direct target of mRNA splicing defect has been identiﬁed that can ex-
plain SMA pathogenesis, and there is equally sparse evidence to support
the hypothesis that defects of distal mRNA transport and localization
lead to SMA. Despite these unanswered questions concerning disease
development and progression, much has been gleaned by modeling
SMA with laboratory model systems. Here, we review the animal
model systems that have been developed, as well as new mechanistic
insights, diagnostic and treatment strategies that have been identiﬁed
using these models.1.1. Caenorhabditis elegans
The nematode Caenorhabditis elegans has been an efﬁcientmodel for
studying various disease-related gene functions. Geneticmutations in C.
elegans can be induced by exposingworms tomutagens, including ethyl
methanesulfonate (EMS) and gamma irradiation. RNA interference
(RNAi)-mediated knockdown of gene expression can be easily achieved
by feeding worms with small interfering RNA (siRNA) libraries. The C.
elegans genome contains a single SMN ortholog, smn-1, that encodes
an SMN protein 36% identical to the human ortholog (Fig. 1) [6]. Reduc-
ing the expression of smn-1 by RNAi causes larval lethality, suggesting
that smn-1 is essential for survival of C. elegans animals [67]. A null mu-
tation of smn-1, smn-1(ok355), that deletesmost of the smn-1 coding re-
gion, causes developmental arrest, reduced lifespan and progressive
loss of motor functions [10]. Neuronal expression of an smn-1 transgene
partially rescues the developmental arrest and motor defects, whilemuscle-speciﬁc expression of the transgene does not, suggesting that
the C. elegans smn-1 primarily functions in neurons [10].
Extensive genetic screens have been performed to identify genes
capable of modifying the deleterious phenotypes of smn-1-deﬁcient C.
elegans mutants [26]. Among these genes, the small conductance
Ca2+-activated K+ channel (SK channel) was identiﬁed andmanipulat-
ed pharmacologically to seek newmodiﬁers of SMN functions for poten-
tial SMA therapy. Activating the SK channel by the neuroprotective drug
Riluzole improved the motor functions of the C. elegans smn-1(ok355)
null mutant and restored axon outgrowth in Smn-deﬁcient rat hippo-
campal neurons [25], suggesting that genes identiﬁed in these screens
could be potential targets for treating SMN-related defects. A caveat of
using the smn-1(ok355) null mutant for screens is that severe defects
of the mutant make identiﬁcation of modiﬁers of the phenotype very
demanding. To overcome this drawback, a point mutation in smn-1
that mimics a human SMA disease mutation was isolated, which causes
weak motor defects and a slightly reduced lifespan [88]. This mutant
was used to screen a library of chemicals for potential drugs that
could ameliorate themild defects. Six chemicals were identiﬁed for fur-
ther analysis [88]. The most effective ones include two FDA-approved
drugs, 4-AP (a potassium channel blocker) and gaboxadol hydrochlo-
ride (a GABAA receptor agonist), and one novel compound Neu5Ac (a
monosaccharide) [88]. With this, the C. elegans smn-1 mutants repre-
sent an efﬁcient discovery tool for performing large-scale screen for
modiﬁers of SMN function.
1.2. Drosophila
TheDrosophila genome contains a single copy of SMN ortholog, Smn,
with 41% sequence homology to human SMN1 (Fig. 1) [66]. Ectopic
expression of SMA disease-related human SMN1 or truncated forms of
Drosophila SMN causes pupal lethality and developmental arrest in a
dominant-negative manner [66], suggesting that Smn is essential for
Drosophila survival. Consistentwith thisﬁnding, theDrosophila ortholog
of Gemin 3, an SMN-interacting protein, is required for larva motor
functions and animal survival [18,87].Drosophilamodels carryingdiffer-
ent Smn mutations have been developed and extensively studied.
Mutant animals carrying an Smn point mutation similar to that in
human SMA patients exhibit reduced excitatory post-synaptic currents,
disorganized motor neuron boutons, loss of glutamate receptors at the
neuromuscular junctions and compromised motor abilities [19].
HypomorphicDrosophila Smnmutants isolated by Rajendra et al display
defective axonal arborization in motor neurons and a failure to form
thin ﬁlaments in muscles [78]. Altogether, these studies establish an es-
sential role for Smn in regulating motor neuron and neuromuscular
functions in Drosophila.
The analysis of mouse Smn mutants has identiﬁed defective
expression of bothmajor intron snRNAs andminor intron snRNAs, con-
sistent with the role of Smn in snRNP assembly and pre-mRNA splicing
[8,30,98]. Reduced snRNA expression was also observed in smn-
deﬁcient S. pombe [14]. Conversely, major intron snRNA expression in
Smn-deﬁcient Drosophila was not obviously affected [78], and reduced
expression of minor intron snRNAs does not apparently affect the splic-
ing of minor introns [77], suggesting that the effects of Smn on snRNA
expression is species-dependent.
That the splicing of bothmajor andminor intronswas altered in Smn
mousemutants raises the question as to which intron type accounts for
AB
Fig. 1. SMNprotein sequence and function are conserved across species during evolution. A. Phylogenetic tree based on SMNprotein sequence showing the genetic divergence among SMN
from different species using the neighbor joining method. B. Amino acid sequence alignment of SMN proteins from different organisms. Identical and similar amino acids are outlined.
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recently demonstrated to exhibit altered splicing in Smn-deﬁcient Dro-
sophila andmammalian cells [52], amongwhich the defective splicing of
the Stasimon gene appears to partially underlie the deﬁcient neuromus-
cular function and improper muscle development [52]. However, stud-
ies from two other groups suggest that defects in minor intron splicing
is an unlikely, if even possible, contributor to themutant phenotypes of
either Smn-deﬁcient Drosophila [31] or mice [99]. Instead, these studies
identiﬁed signiﬁcant expression changes of genes involved in stress
response [31] or altered splicing of genes involved in synaptogenesis
[99]. Therefore it remains an open question as to how defective splicing
of genes with major or minor introns contributes to Smn mutant
phenotypes.
Drosophila Smnmutants have been used in screens for genes that in-
teract with Smn, which identiﬁed members of the BMP signaling path-
ways [20] and genes involved in endocytosis and RNA processing [26].
Combining genetic screens and bioinformatics analyses, Sen et al
recently identiﬁed hundreds of candidate Smn-interacting genes [85].
The most signiﬁcant interactors identiﬁed in this study are a group of
RNA splicing factors [85], which is consistent with our current knowl-
edge that SMN primarily functions in regulating RNA splicing.
Studies in Drosophila have also uncovered new functions of Smn.
Drosophila Smn is required for the integrity of the germline U body-P
body pathway [48], the expression of FGF signaling components [86],
stem cell division and differentiation [33], sensory–motor circuit func-
tion [42], and chronic glutamate receptor-dependent developmental
homeostasis [93]. All of these directions warrant future study.
2. Zebraﬁsh SMA models
The zebraﬁsh (Danio rerio) is an excellent model organism for
neurogenetics research because of its conserved yet simpliﬁed verte-
brate nervous system, the ability to make transgenic animals with rela-
tive ease and to perform forward and reverse genetic studies [34]. Dueto its well-characterized motor neuron circuits and relatively simple
neuromuscular organization, zebraﬁsh is well suited for analyzing neu-
romuscular defects and motor neuron diseases [23,63,79]. The optical
transparency of zebraﬁsh embryos offers accessibility ofmotor neurons,
which can be manipulated in vivo for imaging, electrophysiology and
motor behavioral studies [15,61–63]. The zebraﬁsh spinal cord primary
motor neurons are commonly used to study changes in axon morphol-
ogy, protein aggregation, and neuromuscular junction formation,which
are highly relevant to SMA pathogenesis [11,15,24,63]. Many tech-
niques such as transgenesis and gene knockdown/knockout can be
achieved in zebraﬁsh, enhancing the power of this model for genetic
studies. Zebraﬁsh DNA has been adapted by deliberate mutation at
targeted locations using transcription activator-like effector nucleases
(TALENs) [40] or CRISPR-Cas [41] mediated gene knockout. Morpholino
antisense oligos or in vitro transcribed RNA can be injected into
zebraﬁsh embryos to knockdown or over-express target genes, respec-
tively. The resulting effects can be thoroughly assessed in the transpar-
ent embryo at the level of the entire organism, providing an excellent
tool for assessment of gene function. Transgenic zebraﬁsh expressing
disease-related human proteins can serve as models for speciﬁc
human diseases. With the zebraﬁsh genome project nearly complete
and innovative assays being developed, this model organism will be-
come an increasingly important tool for dissecting motor neuron func-
tions in physiological and pathological conditions.
Initial experiments aimed at characterizing the effects of inhibiting
Smn protein in zebraﬁshwere carried out via smn-targetedmorpholino
antisense oligo injection into one to four cell stage embryos [63]. This is
a common method used to yield transient knockdown by way of bind-
ingmRNA or pre-mRNA, thus interfering with its translation or splicing,
respectively. Antisense morpholino (MO) knockdown of smn in
zebraﬁsh recapitulates many aspects of motor neuron defects in SMA
disease, including truncation and ectopic branching of motor axons
[63]. These motor neuron defects can be rescued by the expression of
wild type smn but notmutatedΔ7smn identiﬁed in humanpatients [63].
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muscle segments in morpholino-injected zebraﬁsh with ~60% Smn
reduction revealed prominent early deﬁcits of axonal branching and
truncation [63]. An important ﬁnding from the characterization of this
in vivo model was that motor axon development is the ﬁrst phenotypic
consequence of reduced Smn protein, preceding apoptosis. Moreover,
thatmuscle development proceeds as normal in themorphant indicates
that in zebraﬁsh motor neuron-speciﬁc developmental deﬁcits drive
denervation and the skeletal muscle phenotypes characteristic of SMA.
Recently, a large-scale reverse genetics screen yielded three promis-
ing smnmutants: two stop mutations (smnY267stop and smnL265stop),
and one exon 7 missense mutation (smnG264D) which was found to
correspond to a human mutation (SMNG279V) known to cause SMA
[7]. All of these mutations manifested in Smn protein reduction and/or
instability, and homozygous embryos had a reduced body axis length
and overall size. Characterization of these mutants revealed a selective
decrease in the synaptic vesicle protein SV2, which was rescued by
the motor neuron-speciﬁc expression of human SMN1. These results
may suggest an important role for Smn in promoting presynaptic integ-
rity [7]. Building on these studies, new zebraﬁsh SMA models were
generated by expressing a human SMN2 transgene in zebraﬁsh carrying
endogenous smn mutations to more closely resemble the genetic
characteristics of human SMA [37]. Characterization of this model
revealed that SMN2 is similarly spliced in ﬁsh as in humans, producing
low levels of full-length SMN protein and comparatively high levels of
exon 7 excluded protein. Furthermore, the manipulation of SMN2
transcripts via an antisense oligonucleotide sequence directed against
an intronic splicing silencer site in intron 7 was sufﬁcient to promote
exon 7 inclusion, thus increasing full-length SMN levels [37]. As the
organism exhibits rapid ex utero development and ease of genetic and
molecular manipulation, this model will prove invaluable in building
the knowledge base of SMA disease development and progression, as
well as serve an in vivo entry point into drug testing and therapy
development.
3. Mouse SMA models
Similar to other subprimates and unlike humans, mice contain only
one survival motor neuron gene, Smn1. Homozygous knockout of
Smn1 in mice leads to massive cell death during early embryonic blas-
tocyst formation resulting in lethality [84]. This suggests essential
biological functions of SMN protein. To test the tissue-speciﬁc require-
ment of Smn1 expression, conditional alleles have been generated.
Neuronal tissue-speciﬁc knockout of Smn1 leads to progressive loss of
motor axons and motor neurons [29], while muscle-restricted Smn1
mutantmice display ongoingmuscle necrosis with a dystrophic pheno-
type leading to paralysis and death. The dystrophic phenotype is associ-
ated with elevated levels of creatine kinase activity and reduction of
dystrophin [22]. The observations from muscle-speciﬁc Smn1 mutant
mice suggest a primary involvement of skeletal muscle in human
SMA, which may contribute to motor defects in addition to motor neu-
ron degeneration.
To recapitulate the genetic foundation of human SMA, mouse
models have been generated by expressing different copies of human
SMN2 through gene targeting or transgenesis on the background of
homozygous disruption of Smn1 gene. Phenotypic manifestations of
severe (type I), intermediate (type II), and mild (type III) forms of
SMA in different mouse models correlate directly with SMN expression
levels [73,84], which is consistent with clinical observations in human
patients. Among the most widely used SMA mouse models are the
Smn1−/−;SMN2tg/tg;SMNΔ7tg/tg (theΔ7 SMAmice or Jackson Laboratory
stock #005025) [47] and the Smn1hung−/−;SMN2Hungtg/tg (theHung-Li
SMAmice or Jackson laboratory stock #005058) [38]. Bothmodels have
an average lifespan of approximately 13 days and exhibit symptoms
and neuropathology similar to patients afﬂicted with intermediate
type II SMA [38,47]. Dr. Hung Li's laboratory established one of theﬁrst intermediate type II SMA modes by building upon an Smn1hung
null mutant created independently by his group with the introduction
of a transgene encoding a full-length SMN2 (SMN2Hung) [38].
Intercrossing of animals hemizygous for the SMN2Hung transgene and
heterozygous for the Smn1 targeted mutation yields progeny that are
hemizygous, homozygous or wild type for the transgene. As expected,
mice carrying varying copies of the transgene exhibited differing levels
of disease severity, thus this model has the ability to yield severe, inter-
mediate and mild SMA phenotypes all within the same litter [38]. Mice
from this model that are hemizygous for the transgene and homozy-
gous for the targeted mutation (Smn1hung −/−; SMN2Hungtg/−) have
very similar phenotypes as the intermediate type II mice generated
from the most widely used Δ7 SMA mice described below [32,38]. Be-
cause this SMA model only has two genetically modiﬁed alleles, it is
particularly useful for crossing with other mice carrying potential dis-
ease modifying targeted mutations or transgenes to generate com-
pound mutant mice.
On the basis of the of Smn1 knockout mice generated in Dr. Michael
Sendtner's laboratory [84], Monani et al. from Dr. Arthur Burghes' labo-
ratory generated the Smn1−/−;SMN2tg/tg (Jackson Laboratory stock
#005024) mice that express a transgene encoding the full-length
SMN2 [70]. These mice are born with normal numbers of spinal motor
neuron, but die aroundpostnatal day 5with a 40% loss ofmotor neurons
and represent severe type I SMA [70]. This effect motivated the same
group to add another transgene encoding a human SMN2 cDNA (SMN
Δ7) lacking exon 7 under the control of the human SMN2 promoter.
The resulting Smn1−/−;SMN2tg/tg;SMNΔ7tg/tg (the Δ7 SMA mice or Jack-
son Laboratory stock #005025) mice, serving as a model for type II in-
termediate SMA, have been the work-horse of the research ﬁeld. The
beneﬁcial effects of SMNΔ7 product demonstrate that up-regulation of
SMN2 can positively modify the SMA pathology. The Δ7 SMA mice die
around 13.3 days after birth, with the loss of approximately 50% of spi-
nal cord α-motor neurons (Fig. 2). As in Drosophila, loss of motor neu-
rons in the Δ7 SMA mice occurs subsequent to the neuromuscular
junction defects that affect both the pre-synaptic nerve terminal and
the post-synaptic muscle ﬁbers. Structural and functional abnormalities
at neuromuscular junctions have been shown to occur before the onset
of weakness, as low SMN levels arrest the postnatal development of
neuromuscular junctions and impair the maturation of acetylcholine
receptor clustering [43,50,58]. In addition to defects in peripheral
synapses, glutamatergic excitatory synapse formation on spinal motor
neurons is also compromised, potentially contributing to excitotoxicity
in motor neurons affected by SMA [51,65]. Inhibitors of histone
deacetylase have been used to increase SMN expression and to correct
pathological defects in Δ7 SMA mice [4,60,89].
Phenotypic analysis also demonstrates that genetic background
plays a key role in the survival of the Δ7 SMA mice. When backcrossed
to complete congenic C57BL/6 J genetic background, the Δ7 SMA mice
exhibit more severe phenotypes, with only 8% of the expected 25% sur-
vival rate to birth, suggesting that each mouse strain has unique back-
ground alleles that may interact with and modify the expression of a
mutation or transgene. More recently, when the SMNΔ7 transgene
was replaced with an SMN1 A2G missense mutation, a mouse model
(Smn1−/−;SMN2tg/tg;SMN1A2G, stock #005026) was generated [69].
These mice exhibit mild type III SMA phenotypes characterized by
motor axon sprouting and loss, muscle atrophy and abnormal EMG pat-
terns [69]. In addition, when a high copy number SMN2 transgene
SMN2(566) was incorporated into the Smn1 knockout mice, the
resulting mouse strain (Smn1−/−;SMN2(566) or Jackson laboratory
stock #008206) expresses 16 copies of SMN2 transgenewhenmade ho-
mozygous [70]. The increased copies of SMN2 rescue these mice from
overt SMA phenotypes except that mice homozygous for both Smn1
targetedmutation and SMN2(566) transgene showa shorter and thicker
tail [70]. A list of the most widely used SMA mouse models, including
their genetic underpinning, phenotypes and ordering information
from Jackson Laboratory is shown in Table 2.
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SMN is expressed ubiquitously in all somatic cells; however, reduced
SMN levels make spinal motor neurons particularly vulnerable to
degeneration. The underlying reasons are not understood, though
some hypotheses regarding SMA disease mechanism may begin to ex-
plain. In accordance with SMN's role in pre-mRNA splicing [75], it has
been proposed that transcripts encodingproteins vital formotor neuron
function and survival may depend on SMN. This hypothesis has been
supported by the identiﬁcation of genes with altered splicing in SMA
mouse models [5,98,99]. Utilizing the newly developed deep sequenc-
ing approach to identify splicing defects in spinal motor neurons affect-
ed by SMA will likely lead to more candidate splicing target genes for
veriﬁcation. Another attractive, and not mutually exclusive, potentialexplanation for the motor neuron-speciﬁc vulnerability lies in the
mislocalization of RNAs in the distal segments of motor axons in SMA
mice [80]. Given that these axons are particularly long, subcellular
RNA localization presents a daunting challenge for these cells. A demon-
strated defect in transportation of the related transcripts or RNA pro-
cessing machinery would be expected to explain the cellular
speciﬁcity of SMA. However, much vital evidence in accordance with
this hypothesis is lacking. A deﬁnitive mechanism linking reduced
SMN levels with axonal transport deﬁciency resulting in motor neuron
dysfunction and atrophy in an SMAmodelwill be required. Importantly,
despite the utility of SMA models, there are several considerations that
must be made with their use and interpretation of the data they yield.
For example, although SMA is a disease affecting primarily the nervous
and motor systems, our understanding of these systems' defects might
Table 2
Widely used spinal muscular atrophy mouse models.
Common name Jackson Stock # SMA type Mortality Genotype Phenotype
Smn1 targeted mutation 006214 Severe
(type I)
Embryonic lethal Smn1−/− Created in the laboratory of Dr. Michael Sendtner. Exon
2 of the mouse Smn1 gene was disrupted by a
neomycin cassette and a lacZ gene fused to the ﬁrst 40
nucleotides of the disrupted exon 2.
Burghes' Severe Model 005024 Severe
(type I)
Stillborn or 4–6 days Smn1−/−;SMN2tg/tg Low birth weight, decreased suckling and movement,
tremoring limbs, and labored breathing.
Δ7 mouse 005025 Intermediate
(type II)
Mean survival
of 13 days
Smn1−/−; SMN2tg/tg;SMNΔ7tg/tg The work-horse and the most widely used model in the
ﬁeld. By postnatal day 5 (P5), signs of muscle weakness
appear and become progressively more pronounced
with an abnormal gait, shakiness in the hind limbs and
a tendency to fall. Severe NMJ defects and loss of over
50% of spinal motor neurons by P9.
Hung-Li mouse 005058 Intermediate
(type II)
Mean survival
of 13 days
Smn1hung−/−; SMN2Hungtg/− Mice hemizygous for the transgene and homozygous
for the targeted mutation exhibit phenotypes similar to
the Δ7 SMA mice. Because only contains two geneti-
cally modiﬁed alleles, this model is particularly useful
for crossing with other mice carrying potential disease
modifying targeted mutations or transgenes.
A2G mouse 005026 Mild
(type III)
Shortened lifespan
of less than 1 year
Smn1−/−; SMN2tg/tg;SMN1A2G Lower body weight, diminished activity, muscle
weakness, motor axon sprouting and loss, muscle
atrophy and abnormal EMG patterns. The Jackson Lab-
oratory notes a milder phenotype than the original
publication.
008206 Very mild
(type IV)
None Smn1−/−;SMN2(566) Homozygous mice have 16 copies of SMN2. No overt
features of SMA. Shorter and thicker tail.
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entirely possible that the motor defects observed are not direct, but
rather indirect consequences of SMN mutations.
Spinal muscular atrophy has historically been considered a pure
motor neuron disorder. However, recent studies have shown that in
severe type 1 SMA, other organs can also be involved [36,57]. In one re-
port, three of four patients with only one copy of SMN2 had hemody-
namically relevant atrial or ventricular septal defects. These patients
required mechanical ventilation at birth and survived only a few
months [82]. In another report, two unrelated patients with severe
SMA type I and only one SMN2 copy developed ulcerations and necroses
of the ﬁngers and toes. Sural nerve biopsy was normal in one patient,
but skin biopsy showed thrombotic occlusion of the small vessels caus-
ing perfusion abnormalities and tissue necrosis, suggesting that SMN
deﬁciency may present as a vasculopathy [83]. In a previous study,
these same authors performed sural nerve biopsies on 19 patients
with SMA I through III and noted signiﬁcant sensory nerve pathology
in severely affected patients with SMA type I. None of the patients
with SMA type II or III had any evidence of clinical or pathological sen-
sory nerve alterations [81]. These extra-neuronal manifestations seem
to occur in severe SMApatientswith only one copy of SMN2 and usually
require supportive respiratory measure at birth.
Due to the lack of understanding of disease mechanism, there is cur-
rently no cure for SMA. As the number of clinical trials continues
expanding, the availability of reliable biomarkers will be crucial for an
objective measurement of disease progression, monitoring of response
to treatment and shortening of trial duration. Electrophysiological bio-
markers that assess motor units in vivo, including compound muscle
action potential (CMAP) and motor unit number estimate (MUNE),
have been tested in SMA clinical trials [92]. Although CMAP and
MUNE showed some correlation with disease phenotype and SMN2
copy number [91] and seemed to increase in response to valproic acid
treatment, the trial was negative. SMN protein and transcript levels
can be easily measured in peripheral blood. However these levels do
not seem to correlate with disease severity [90]. More recently bio-
markers from a large multicenter SMA study “BforSMA” used proteo-
mic, metabolomic and transcriptomic approaches to identify candidate
proteins, plasma and urine metabolite markers that correlated with
motor scores in a wide range of SMA patients [27]. Using these datasets, a commercial biomarker panel (SMA-MAP) for plasma proteins
in SMA patients was developed. This panel includes 27 analytes and
showed a signiﬁcant association with motor functions and other mea-
sures of SMA disease activity [45]. An ongoing natural history study,
NeuroNex, conducted by the Network for Excellence in Neuroscience
Clinical Trials, is collecting motor function measures, molecular
biomarkers (SMN protein and transcript levels as well as SMA-MAP)
and electrophysiological markers (CMAP and electric impedance
myography) in the immediate post natal period of afﬂicted infants in
order to validate these measures and to facilitate the future conduct of
clinical trials in these cohorts.
Although at present there is no cure for SMA, a number of promising
advancements have been made in search of treatment. Current thera-
peutic strategies under development are almost exclusively based on
trying to increase levels of SMN protein. These include expression of
ectopic SMN by gene therapy [28], increasing inclusion of exon 7 in
SMN2mRNA transcripts, upregulation of SMN transcription by promot-
er activation or correcting splicing defects [2,9,39,55], modulation of
SMN protein translation [53,60,97], and prevention of SMN protein
degradation [21,95]. Some histone deacetylase (HDAC) inhibitors have
been demonstrated to increase the production of full-length SMN
from SMN2 by promoting exon 7 inclusion, in addition to enhancing
gene expression levels by promoting histone acetylation and open chro-
matin structure [2,4,9,89]. However, altered gene expression on a more
global basis was also observed, suggesting undesired side effects of
nonspeciﬁc HDAC inhibitors as therapeutic agents. Recently, signiﬁcant
progress has been made in developing gene therapy for SMA following
the surprising ﬁnding that scAAV9 can mediate SMN1 expression very
speciﬁcally in spinal motor neurons [28]. In addition, antisense oligonu-
cleotides targeted to SMN2 pre-mRNA have been developed as a
prototype for potential treatment. These oligos have been shown to ef-
fectively modulate the splicing of SMN2, resulting in the production of
transcripts with exon 7 inclusion, thus elevating the level of functional
SMN [39]. Recent rapid progress in stem cell research, including the de-
velopment of induced pluripotent stem (iPS) cells from SMA patient ﬁ-
broblasts [100], presented the possibility of using motor neurons
derived from iPS cells, or other stem cell sources, to replace degenerated
motor neurons in SMA patients, study disease pathogenesis and per-
form drug screening. Because iPS cell-derived motor neurons carry the
691B.M. Edens et al. / Biochimica et Biophysica Acta 1852 (2015) 685–692patient's genetic makeup, their clinical usewill likely improve projected
transplant outcome. Though the challenges facing the application of this
approach in human are appreciable, it may be the only applicable ther-
apy for individuals who’ve already experienced substantial motor neu-
ron loss, since methods aimed at increasing full-length SMN levels can
only act to promote survival inmotor neurons that have not yet initiated
apoptosis. Importantly, the divergence in prognoses given SMA type
designation may warrant the development and application of multiple
therapies.
Taken together, model systems have so far greatly advanced our
understanding of the genetics and biology of SMA. However, a critical
gap still exists in our knowledge about how SMN mutations lead to
SMA pathogenesis: we have little information about the identities of
genes, proteins and other biological factors that mediate the particular
vulnerability of spinal motor neurons. More extensive studies using
these model systems should provide crucial understanding of this
causal effect and contribute to the development of efﬁcacious therapies
for SMA.Acknowledgements
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